FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Seiji Fukumoto

Research Profile

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Yuka Kinoshita; Seiji Fukumoto
[Space flight/bedrest immobilization and bone. Medical treatment for immobilization osteoporosis].
Seiji Fukumoto
[Significance of FGF23 measurement].
Yuka Kinoshita; Tasuku Saito; Yuichiro Shimizu; Manabu Taguchi; Seiji Fukumoto; Michiko Hori; Takashi Igarashi; Toshiro Fujita
Mutational analysis of patients with FGF23-related hypophosphatemic rickets.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Seiji Fukumoto (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Yuka Kinoshita; Seiji Fukumoto
[Space flight/bedrest immobilization and bone. Medical treatment for immobilization osteoporosis].
Clinical calcium 2012;22(12):1895-901.
2012: Seiji Fukumoto
[Significance of FGF23 measurement].
Clinical calcium 2012;22(10):1525-9.
2012: Yuka Kinoshita; Tasuku Saito; Yuichiro Shimizu; Manabu Taguchi; Seiji Fukumoto; Michiko Hori; Takashi Igarashi; Toshiro Fujita
Mutational analysis of patients with FGF23-related hypophosphatemic rickets.
European journal of endocrinology / European Federation of Endocrine Societies 2012;167(2):165-72.
2012: Seiji Fukumoto
[Kidney and bone update : the 5-year history and future of CKD-MBD. CKD-MBD and phosphotropic hormones].
Clinical calcium 2012;22(7):987-91.
2012: Hiroo Kawarazaki; Ryo Kido; Ichiro Nakajima; Yugo Shibagaki; Satoshi Teraoka; Katsuyuki Ando; Shohei Fuchinoue; Toshiro Fujita; Masafumi Fukagawa; Seiji Fukumoto
Kidney transplantation restored uncoupled bone turnover in end-stage renal disease.
Clinical nephrology 2012;78(1):10-6.
2012: Yuka Kinoshita; Seiji Fukumoto
[Parathyroid hormone for disorders of calcium metabolism and metabolic bone diseases other than osteoporosis].
Clinical calcium 2012;22(3):381-6.
2012: Yuichiro Shimizu; Seiji Fukumoto; Toshiro Fujita
Evaluation of a new automated chemiluminescence immunoassay for FGF23.
Journal of bone and mineral metabolism 2012;30(2):217-21.
2011: Seiji Fukumoto
[Physiological and pathophygiological significance of a phosphotropic hormone, FGF23].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2011;100(12):3649-54.
2011: Hiroo Kawarazaki; Ryo Kido; Ichiro Nakajima; Yugo Shibagaki; Katsuyuki Ando; Shohei Fuchinoue; Toshiro Fujita; Masafumi Fukagawa; Seiji Fukumoto; Satoshi Teraoka
Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2011;15(5):481-7.
2011: Tasuku Saito; Yuichiro Shimizu; Manabu Taguchi; Seiji Fukumoto; Michiko Hori; Takashi Igarashi; Toshiro Fujitab
A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene.
Bone 2011;49(4):913-6.
2011: Seiji Fukumoto; Yuichiro Shimizu
Fibroblast growth factor 23 as a phosphotropic hormone and beyond.
Journal of bone and mineral metabolism 2011;29(5):507-14.
2011: Seiji Fukumoto
[Differential diagnosis of hypercalcemia].
Nihon rinsho. Japanese journal of clinical medicine 2011;69 Suppl 2():435-9.
2011: Seiji Fukumoto
[Antagonist for calcium-sensing receptor. JTT-305/MK-5442].
Clinical calcium 2011;21(1):89-93.
2011: Michiko Hori; Yuichiro Shimizu; Seiji Fukumoto
Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism.
Endocrinology 2011;152(1):4-10.
2010: Seiji Fukumoto
[Endocrine diseases].
Nihon rinsho. Japanese journal of clinical medicine 2010;68 Suppl 8():354-8.
2010: Seiji Fukumoto
[FGF23].
Nihon rinsho. Japanese journal of clinical medicine 2010;68 Suppl 7():645-7.
2010: Ayako Kimura; Hiroyuki Inose; Fumiko Yano; Koji Fujita; Toshiyuki Ikeda; Shingo Sato; Makiko Iwasaki; Tetsuya Jinno; Keisuke Ae; Seiji Fukumoto; Yasuhiro Takeuchi; Hiroshi Itoh; Takeshi Imamura; Hiroshi Kawaguchi; Ung-il Chung; James F Martin; Sachiko Iseki; Ken-ichi Shinomiya; Shu Takeda
Runx1 and Runx2 cooperate during sternal morphogenesis.
Development (Cambridge, England) 2010;137(7):1159-67.
2010: Yoshiyuki Mori; Toru Ogasawara; Toru Motoi; Yuichiro Shimizu; Daichi Chikazu; Kazumi Tamura; Seiji Fukumoto; Tsuyoshi Takato
Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2010;109(3):e57-63.
2010: Michiko Hori; Noriko Makita; Takahiro Andoh; Hirotoshi Takiyama; Yuki Yajima; Takashi Sakatani; Seiji Fukumoto; Taroh Iiri; Toshiro Fujita
Long-term clinical course of IgG4-related systemic disease accompanied by hypophysitis.
Endocrine journal 2010;57(6):485-92.
2009: Hiroyuki Inose; Hiroki Ochi; Ayako Kimura; Koji Fujita; Ren Xu; Shingo Sato; Makiko Iwasaki; Satoko Sunamura; Yasuhiro Takeuchi; Seiji Fukumoto; Kuniaki Saito; Takashi Nakamura; Haruhiko Siomi; Hiroshi Ito; Yoshiyasu Arai; Ken-ichi Shinomiya; Shu Takeda
A microRNA regulatory mechanism of osteoblast differentiation.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(49):20794-9.
2009: Seiji Fukumoto
The role of bone in phosphate metabolism.
Molecular and cellular endocrinology 2009;310(1-2):63-70.
2009: Tasuku Saito; Yutaka Nishii; Toshiyuki Yasuda; Nobuaki Ito; Hisanori Suzuki; Takashi Igarashi; Seiji Fukumoto; Toshiro Fujita
Familial hypophosphatemic rickets caused by a large deletion in PHEX gene.
European journal of endocrinology / European Federation of Endocrine Societies 2009;161(4):647-51.
2009: Yuichiro Shimizu; Yuko Tada; Mika Yamauchi; Takaaki Okamoto; Hisanori Suzuki; Nobuaki Ito; Seiji Fukumoto; Toshitsugu Sugimoto; Toshiro Fujita
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Bone 2009;45(4):814-6.
2009: Seiji Fukumoto
[Hormones and osteoporosis update. FGF23/Klotho and bone metabolism].
Clinical calcium 2009;19(7):945-50.
2009: Seiji Fukumoto; T John Martin
Bone as an endocrine organ.
Trends in endocrinology and metabolism: TEM 2009;20(5):230-6.
2009: Yuichiro Shimizu; Seiji Fukumoto
[Clinical aspect of recent progress in phosphate metabolism. The pathophysiology of diseases caused by aberrant actions of FGF23].
Clinical calcium 2009;19(6):802-7.
2009: Seiji Fukumoto
[Chronic kidney disease (CKD) and bone. Regulation of calcium and phosphate metabolism by FGF23/Klotho].
Clinical calcium 2009;19(4):523-8.
2009: Tasuku Saito; Seiji Fukumoto
Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism.
International journal of pediatric endocrinology 2009;2009():496514.
2009: Tasuku Saito; Seiji Fukumoto; Nobuaki Ito; Hisanori Suzuki; Takashi Igarashi; Toshiro Fujita
A novel mutation in the GATA3 gene of a Japanese patient with PTH-deficient hypoparathyroidism.
Journal of bone and mineral metabolism 2009;27(3):386-9.
2008: Seiji Fukumoto; Noriyuki Namba; Keiichi Ozono; Mika Yamauchi; Toshitsugu Sugimoto; Toshimi Michigami; Hiroyuki Tanaka; Daisuke Inoue; Masanori Minagawa; Itsuro Endo; Toshio Matsumoto
Causes and differential diagnosis of hypocalcemia--recommendation proposed by expert panel supported by ministry of health, labour and welfare, Japan.
Endocrine journal 2008;55(5):787-94.
2008: Shingo Sato; Ayako Kimura; Jerfi Ozdemir; Yoshinori Asou; Makiko Miyazaki; Tetsuya Jinno; Keisuke Ae; Xiuyun Liu; Mitsuhiko Osaki; Yasuhiro Takeuchi; Seiji Fukumoto; Hiroshi Kawaguchi; Hirotaka Haro; Kenichi Shinomiya; Gerard Karsenty; Shu Takeda
The distinct role of the Runx proteins in chondrocyte differentiation and intervertebral disc degeneration: findings in murine models and in human disease.
Arthritis and rheumatism 2008;58(9):2764-75.
2008: Seiji Fukumoto
[PTH and mechanical stress].
Clinical calcium 2008;18(9):1327-31.
2008: Yuji Yamazaki; Taro Tamada; Noriyuki Kasai; Itaru Urakawa; Yukiko Aono; Hisashi Hasegawa; Toshiro Fujita; Ryota Kuroki; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shimada
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2008;23(9):1509-18.
2008: Itsuro Endo; Seiji Fukumoto; Keiichi Ozono; Noriyuki Namba; Hiroyuki Tanaka; Daisuke Inoue; Masanori Minagawa; Toshitsugu Sugimoto; Mika Yamauchi; Toshimi Michigami; Toshio Matsumoto
Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Bone 2008;42(6):1235-9.
2008: Seiji Fukumoto
Actions and mode of actions of FGF19 subfamily members.
Endocrine journal 2008;55(1):23-31.
2008: Tetsushi Nasu; Seigo Kurisu; Shohei Matsuno; Kunihiro Tatsumi; Tetsuhiro Kakimoto; Masato Kobayashi; Yoshio Nakano; Hisao Wakasaki; Hiroto Furuta; Masahiro Nishi; Hideyuki Sasaki; Hisanori Suzuki; Nobuaki Ito; Seiji Fukumoto; Kishio Nanjo
Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23.
Internal medicine (Tokyo, Japan) 2008;47(10):957-61.
2008: Eriko Ogura; Kazunori Kageyama; Seiji Fukumoto; Norito Yagihashi; Yoshiko Fukuda; Toru Kikuchi; Mitsuo Masuda; Toshihiro Suda
Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23.
Internal medicine (Tokyo, Japan) 2008;47(7):637-41.
2008: Seiji Fukumoto
Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23.
Internal medicine (Tokyo, Japan) 2008;47(5):337-43.
2008: Seiji Fukumoto
[Basic and clinical aspects of calcimimetics. Structure and function of calcium-sensing receptor].
Clinical calcium 2008;18(1):32-6.
2007: Seiji Fukumoto
[Parathyroid and bone. Calcimimetics and bone metabolism].
Clinical calcium 2007;17(12):1865-9.
2007: Seiji Fukumoto
[Novel phosphate-regulating hormone, fibroblast growth factor (FGF) 23].
Nihon rinsho. Japanese journal of clinical medicine 2007;65 Suppl 9():101-4.
2007: Nobuaki Ito; Seiji Fukumoto
[FGF23-related hypophosphatemic rickets/osteomalacia].
Clinical calcium 2007;17(10):1514-20.
2007: Shingo Sato; Reiko Hanada; Ayako Kimura; Tomomi Abe; Takahiro Matsumoto; Makiko Iwasaki; Hiroyuki Inose; Takanori Ida; Michihiro Mieda; Yasuhiro Takeuchi; Seiji Fukumoto; Toshiro Fujita; Shigeaki Kato; Kenji Kangawa; Masayasu Kojima; Kenichi Shinomiya; Shu Takeda
Central control of bone remodeling by neuromedin U.
Nature medicine 2007;13(10):1234-40.
2007: Hiroo Kawarazaki; Yugo Shibagaki; Hideki Shimizu; Wakako Kawarazaki; Nobuaki Ito; Akira Ishikawa; Seiji Fukumoto; Toshiro Fujita
Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia.
Clinical and experimental nephrology 2007;11(3):255-7.
2007: Nobuaki Ito; Seiji Fukumoto
[Symptoms and management of tetany].
Clinical calcium 2007;17(8):1234-9.
2007: Seiji Fukumoto
[Pseudohypoparathyroidism type I b and genomic imprinting].
Clinical calcium 2007;17(8):1222-7.
2007: Itsuro Endo; Toshio Matsumoto; Seiji Fukumoto
[Pathophysiology and classitication of parathyroidism].
Clinical calcium 2007;17(8):1175-81.
2007: Seiji Fukumoto
[Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
Rinsho byori. The Japanese journal of clinical pathology 2007;55(6):555-9.
2007: Hiroyuki Yamashita; Yuji Yamazaki; Hisashi Hasegawa; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shigematsu; Junichiro James Kazama; Masafumi Fukagawa; Shiro Noguchi
Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.
Endocrine journal 2007;54(3):465-70.
2007: Nobuaki Ito; Seiji Fukumoto; Manabu Taguchi; Akira Takeshita; Yasuhiro Takeuchi; Shozo Yamada; Toshiro Fujita
Fibroblast growth factor (FGF)23 in patients with acromegaly.
Endocrine journal 2007;54(3):481-4.
2007: Seiji Fukumoto
[Transport of minerals in renal tubules and its hormonal regulation].
Clinical calcium 2007;17(5):677-83.
2007: Seiji Fukumoto; Takeyoshi Yamashita
FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.
Bone 2007;40(5):1190-5.
2007: Seiji Fukumoto
[Regulation of phosphorus-vitamin D metabolism by FGF23].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2007;96(4):719-24.
2007: Yaacov Frishberg; Nobuaki Ito; Choni Rinat; Yuji Yamazaki; Sofia Feinstein; Itaru Urakawa; Paulina Navon-Elkan; Rachel Becker-Cohen; Takeyoshi Yamashita; Kaori Araya; Takashi Igarashi; Toshiro Fujita; Seiji Fukumoto
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2007;22(2):235-42.
2007: Nobuaki Ito; Seiji Fukumoto; Yasuhiro Takeuchi; Shu Takeda; Hisanori Suzuki; Takeyoshi Yamashita; Toshiro Fujita
Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans.
Journal of bone and mineral metabolism 2007;25(6):419-22.
2007: Seiji Fukumoto
[ASBMR 2006 Report. Treatment of osteoporosis].
Clinical calcium 2007;17(1):100-2.
2006: Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Klotho converts canonical FGF receptor into a specific receptor for FGF23.
Nature 2006;444(7120):770-4.
2006: Yusuke Shinoda; Masayuki Yamaguchi; Naoshi Ogata; Toru Akune; Naoto Kubota; Toshimasa Yamauchi; Yasuo Terauchi; Takashi Kadowaki; Yasuhiro Takeuchi; Seiji Fukumoto; Toshiyuki Ikeda; Kazuto Hoshi; Ung-il Chung; Kozo Nakamura; Hiroshi Kawaguchi
Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways.
Journal of cellular biochemistry 2006;99(1):196-208.
2006: Seiji Fukumoto
[Tumor-induced rickets/osteomalacia].
Nihon rinsho. Japanese journal of clinical medicine 2006;Suppl 2():96-9.
2006: Noriko Makita; Taroh Iiri; Junichiro Sato; Seiji Fukumoto; Tomoki Okazaki; Kiyomi Yamazaki; Takao Obara; Toshiro Fujita
An instructive case suggesting cyclical primary hyperparathyroidism.
Endocrine journal 2006;53(3):311-6.
2005: Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.
American journal of physiology. Renal physiology 2005;289(5):F1088-95.
2005: Seiji Fukumoto
[Tumor-induced rickets/osteomalacia].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 10():523-8.
2005: Nobuaki Ito; Seiji Fukumoto
[Assay methods for FGF].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 10():498-502.
2005: Kunio Araya; Seiji Fukumoto; Rebecca Backenroth; Yasuhiro Takeuchi; Kounosuke Nakayama; Nobuaki Ito; Nozomi Yoshii; Yuji Yamazaki; Takeyoshi Yamashita; Justin Silver; Takashi Igarashi; Toshiro Fujita
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.
The Journal of clinical endocrinology and metabolism 2005;90(10):5523-7.
2005: Hiroyuki Yamashita; Shiro Noguchi; Yuji Yamasaki; Hisashi Hasegawa; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shigematsu; Junichiro James Kazama; Masafumi Fukagawa
[Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism].
Clinical calcium 2005;15 Suppl 1():41-5; discussion 45.
2005: Seiji Fukumoto
[FGF23 (phosphatonin)].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 8():606-8.
2005: Seiji Fukumoto
Post-translational modification of Fibroblast Growth Factor 23.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2005;9(4):319-22.
2005: Nobuaki Ito; Seiji Fukumoto
[FGF23 and bone metabolism].
Clinical calcium 2005;15(7):43-8.
2005: Hiroyuki Yamashita; Yuji Yamazaki; Hisashi Hasegawa; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shigematsu; Junichiro James Kazama; Masafumi Fukagawa; Shiro Noguchi
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation.
The Journal of clinical endocrinology and metabolism 2005;90(7):4211-5.
2005: Nobuhiro Fukushima; Reiko Hanada; Hitoshi Teranishi; Yoshihiko Fukue; Toshiaki Tachibana; Hiroshi Ishikawa; Shu Takeda; Yasuhiro Takeuchi; Seiji Fukumoto; Kenji Kangawa; Kensei Nagata; Masayasu Kojima
Ghrelin directly regulates bone formation.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2005;20(5):790-8.
2005: Seiji Fukumoto
[New development related to osteoporosis. Parathyroid hormone (PTH)].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2005;94(4):720-3.
2005: Shohei Nakanishi; Junichiro James Kazama; Tomoko Nii-Kono; Kentaro Omori; Takeyoshi Yamashita; Seiji Fukumoto; Fumitake Gejyo; Takashi Shigematsu; Masafumi Fukagawa
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
Kidney international 2005;67(3):1171-8.
2005: Junichiro James Kazama; Fuminori Sato; Kentaro Omori; Hitomi Hama; Suguru Yamamoto; Hiroki Maruyama; Ichiei Narita; Fumitake Gejyo; Takeyoshi Yamashita; Seiji Fukumoto; Masafumi Fukagawa
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.
Kidney international 2005;67(3):1120-5.
2005: Nobuaki Ito; Seiji Fukumoto; Yasuhiro Takeuchi; Toshiyuki Yasuda; Yukihiro Hasegawa; Fumi Takemoto; Toshihiro Tajima; Kazushige Dobashi; Yuji Yamazaki; Takeyoshi Yamashita; Toshiro Fujita
Comparison of two assays for fibroblast growth factor (FGF)-23.
Journal of bone and mineral metabolism 2005;23(6):435-40.
2005: Hiroshi Nishi; Tomoko Nii-Kono; Shohei Nakanishi; Yuji Yamazaki; Takeyoshi Yamashita; Seiji Fukumoto; Kazuto Ikeda; Akira Fujimori; Masafumi Fukagawa
Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism.
Nephron. Clinical practice 2005;101(2):c94-9.
2004: Nobuaki Ito; Seiji Fukumoto
[Significance of a new PTH assay (the comparison between whole-PTH and intact-PTH assay)].
Clinical calcium 2004;14(9):55-6.
2004: Yasuhiro Takeuchi; Hisanori Suzuki; Sayoko Ogura; Rie Imai; Yuji Yamazaki; Takeyoshi Yamashita; Yoshinari Miyamoto; Hiroshi Okazaki; Kozo Nakamura; Kazuhiko Nakahara; Seiji Fukumoto; Toshiro Fujita
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.
The Journal of clinical endocrinology and metabolism 2004;89(8):3979-82.
2004: Takashi Shigematsu; Junichiro James Kazama; Takeyoshi Yamashita; Seiji Fukumoto; Tatsuo Hosoya; Fumitake Gejyo; Masafumi Fukagawa
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2004;44(2):250-6.
2004: Hiroyuki Yamashita; Takeyoshi Yamashita; Masashi Miyamoto; Takashi Shigematsu; Junichiro James Kazama; Takashi Shimada; Yuji Yamazaki; Seiji Fukumoto; Masafumi Fukagaw; Shiro Noguchi
Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism.
European journal of endocrinology / European Federation of Endocrine Societies 2004;151(1):55-60.
2004: Seiji Fukumoto
[phosphorus metabolism disorders and FGF-23].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2004;93(6):1211-6.
2004: Seiji Fukumoto
[Nephrocalcinosis].
Clinical calcium 2004;14(6):34-7.
2004: Seiji Fukumoto
[Genes affecting bone quality].
Clinical calcium 2004;14(4):604-5.
2004: Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2004;19(3):429-35.
2004: Takashi Shimada; Itaru Urakawa; Yuji Yamazaki; Hisashi Hasegawa; Rieko Hino; Takashi Yoneya; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.
Biochemical and biophysical research communications 2004;314(2):409-14.
2004: Takashi Shimada; Makoto Kakitani; Yuji Yamazaki; Hisashi Hasegawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Kazuma Tomizuka; Takeyoshi Yamashita
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.
The Journal of clinical investigation 2004;113(4):561-8.
2004: Seiji Fukumoto; Kazuhiko Nakahara
[Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases].
Rinsho byori. The Japanese journal of clinical pathology 2004;52(1):51-4.
2003: Emiko Tohjima; Daisuke Inoue; Nobuchika Yamamoto; Shinsuke Kido; Yuji Ito; Shuji Kato; Yasuhiro Takeuchi; Seiji Fukumoto; Toshio Matsumoto
Decreased AP-1 activity and interleukin-11 expression by bone marrow stromal cells may be associated with impaired bone formation in aged mice.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(8):1461-70.
2003: Seiji Fukumoto; Takeyoshi Yamashita
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
The New England journal of medicine 2003;349(5):505-6; author reply 505-6.
2003: Seiji Fukumoto
[Calcium and vitamin D metabolism in paraneoplastic syndromes].
Clinical calcium 2003;13(7):908-10.
2003: Konosuke Nakayama; Yasuhiro Tamura; Miyuki Suzawa; Shun-Ichi Harada; Seiji Fukumoto; Mitsuyasu Kato; Kohei Miyazono; Gideon A Rodan; Yasuhiro Takeuchi; Toshiro Fujita
Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(5):827-35.
2003: Seiji Fukumoto
[Treatment of bone metastases].
Clinical calcium 2003;13(4):483-6.
2003: Noriko Chikatsu; Sumiyo Watanabe; Yasuhiro Takeuchi; Yasushi Muraosa; Shinsuke Sasaki; Yuji Oka; Seiji Fukumoto; Toshiro Fujita
A family of autosomal dominant hypocalcemia with an activating mutation of calcium-sensing receptor gene.
Endocrine journal 2003;50(1):91-6.
2003: Sumiyo Watanabe; Yasuhiro Takeuchi; Seiji Fukumoto; Hiroko Fujita; Tadasumi Nakano; Toshiro Fujita
Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients.
Journal of bone and mineral metabolism 2003;21(3):166-71.
2002: Yasuhiro Takeuchi; Sumiyo Watanabe; Genichiro Ishii; Shu Takeda; Konosuke Nakayama; Seiji Fukumoto; Yasuyuki Kaneta; Daisuke Inoue; Toshio Matsumoto; Kenichi Harigaya; Toshiro Fujita
Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice.
The Journal of biological chemistry 2002;277(50):49011-8.
2002: Miho Honda; Seiji Fukumoto; Toshiro Fujita; Yoshitomo Oka; Tomoichiro Asano
Association of HLA-CW3 with type 1 diabetes mellitus and idiopathic hypoparathyroidism in the Japanese.
Endocrine journal 2002;49(6):653-4.
2002: Noriyuki Hanibuchi; Takao Maruyama; Masakazu Menju; Hiroyuki Toyoshima; Takehisa Yamamoto; Seiji Fukumoto; Ichiro Konishi
Marked hypercalcemia in a patient with hypocalciuric hypercalcemia without a mutation in the calcium-sensing receptor gene.
Internal medicine (Tokyo, Japan) 2002;41(12):1153-7.
2002: Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
The Journal of clinical endocrinology and metabolism 2002;87(11):4957-60.
2002: Sumiyo Watanabe; Seiji Fukumoto; Hangil Chang; Yasuhiro Takeuchi; Yukihiro Hasegawa; Ryo Okazaki; Noriko Chikatsu; Toshiro Fujita
Association between activating mutations of calcium-sensing receptor and Bartter's syndrome.
Lancet 2002;360(9334):692-4.
2002: Noriko Chikatsu; Yasuhiro Takeuchi; Seiji Fukumoto; Kazuki Yano; Naoya Fujita; Takashi Tsuruo; Toshiro Fujita
Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro.
Endocrine journal 2002;49(4):439-47.
2002: Takashi Shimada; Takanori Muto; Itaru Urakawa; Takashi Yoneya; Yuji Yamazaki; Katsuya Okawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.
Endocrinology 2002;143(8):3179-82.
2002: Seiji Fukumoto; Takeyoshi Yamashita
Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
Current opinion in nephrology and hypertension 2002;11(4):385-9.
2002: Terumasa Nagase; Takehiko Murakami; Toshihiko Tsukada; Ryuichi Kitamura; Noriko Chikatsu; Hiroki Takeo; Nobuki Takata; Hiroko Yasuda; Seiji Fukumoto; Yuji Tanaka; Naokazu Nagata; Ken Yamaguchi; Takuhiko Akatsu; Michiko Yamamoto
A family of autosomal dominant hypocalcemia with a positive correlation between serum calcium and magnesium: identification of a novel gain of function mutation (Ser(820)Phe) in the calcium-sensing receptor.
The Journal of clinical endocrinology and metabolism 2002;87(6):2681-7.
2002: Yasuhiro Takeuchi; Seiji Fukumoto; Konosuke Nakayama; Yasuhiro Tamura; Akio Yanagisawa; Toshiro Fujita
Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2002;17(5):753-7.
2002: Seiji Fukumoto
[Practice guidelines review: Pseudohypoparathyroidism].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2002;91(4):1257-70.
2002: Seiji Fukumoto
[Calcium-sensing receptor in bone cells].
Nihon rinsho. Japanese journal of clinical medicine 2002;60 Suppl 3():57-63.
2002: Sumiyo Watanabe; Seiji Fukumoto
[Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism caused by inactivating mutations of calcium-sensing receptor].
Nihon rinsho. Japanese journal of clinical medicine 2002;60(2):325-30.
2002: Miyuki Suzawa; Yasuhiro Tamura; Seiji Fukumoto; Kohei Miyazono; Toshiro Fujita; Shigeaki Kato; Yasuhiro Takeuchi
Stimulation of Smad1 transcriptional activity by Ras-extracellular signal-regulated kinase pathway: a possible mechanism for collagen-dependent osteoblastic differentiation.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2002;17(2):240-8.
2001: Seiji Fukumoto
[Activating mutations of calcium-sensing receptor cause insufficient secretion of parathyroid hormone].
Clinical calcium 2001;11(12):1633-6.
2001: Seiji Fukumoto; Takeyoshi Yamashita
Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia.
Endocrine journal 2001;48(6):603-10.
2001: Seiji Fukumoto
[Idiopathic hypoparathyroidism].
Nihon rinsho. Japanese journal of clinical medicine 2001;59 Suppl 8():101-7.
2001: Seiji Fukumoto; Noriko Chikatsu; Ryo Okazaki; Yasuhiro Takeuchi; Yasuhiro Tamura; T Murakami; Takao Obara; Tomoyuki Fujita
Inactivating mutations of calcium-sensing receptor results in parathyroid lipohyperplasia.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2001;10(4):242-7.
2001: Yasuhiro Tamura; Yasuhiro Takeuchi; Miyuki Suzawa; Seiji Fukumoto; Masayoshi Kato; Kohei Miyazono; Tomoyuki Fujita
Focal adhesion kinase activity is required for bone morphogenetic protein--Smad1 signaling and osteoblastic differentiation in murine MC3T3-E1 cells.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2001;16(10):1772-9.
2001: Nobuo Sekine; Seiji Fukumoto; T Ishikawa; T Okazaki; Tomoyuki Fujita
GH inhibits interferon-gamma-induced signal transducer and activator of transcription-1 activation and expression of the inducible isoform of nitric oxide synthase in INS-1 cells.
Endocrinology 2001;142(9):3909-16.
2001: Takashi Shimada; S Mizutani; Takanori Muto; Takashi Yoneya; Rieko Hino; S Takeda; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(11):6500-5.
2000: Yasuhiro Takeuchi; Miyuki Suzawa; Seiji Fukumoto; Tomoyuki Fujita
Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures.
Bone 2000;27(6):769-76.
2000: Noriko Chikatsu; Seiji Fukumoto; Yasuhiro Takeuchi; Miyuki Suzawa; Takao Obara; Toshio Matsumoto; Tomoyuki Fujita
Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas.
The Journal of biological chemistry 2000;275(11):7553-7.
2000: Noriko Chikatsu; Yasuhiro Takeuchi; Yasuhiro Tamura; Seiji Fukumoto; K Yano; E Tsuda; Etsuro Ogata; Tomoyuki Fujita
Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.
Biochemical and biophysical research communications 2000;267(2):632-7.
1999: Ryo Okazaki; M Miura; M Toriumi; M Taguchi; Y Hirota; Seiji Fukumoto; Tomoyuki Fujita; K Tanaka; A Takeuchi
Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
Endocrine journal 1999;46(6):795-801.
1999: Ryo Okazaki; M Toriumi; Seiji Fukumoto; M Miyamoto; Tomoyuki Fujita; K Tanaka; Yasuhiro Takeuchi
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Endocrinology 1999;140(11):5060-5.
1999: Seiji Fukumoto; Yasuhiro Takeuchi; A Nagano; Tomoyuki Fujita
Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia.
Bone 1999;25(3):375-7.
1999: Miyuki Suzawa; Yasuhiro Takeuchi; Seiji Fukumoto; Shigeaki Kato; N Ueno; Kohei Miyazono; T Matsumoto; Tomoyuki Fujita
Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro.
Endocrinology 1999;140(5):2125-33.
1999: Junko Yasufuku-Takano; Koji Takano; T Takei; Seiji Fukumoto; Akira Teramoto; Kintomo Takakura; Naohide Yamashita; Tomoyuki Fujita
Heterozygous gsp mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone.
Endocrinology 1999;140(5):2018-26.
1999: Noriko Chikatsu; Seiji Fukumoto; Miyuki Suzawa; Yuji Tanaka; Yasuhiro Takeuchi; S Takeda; Yasuhiro Tamura; Toshio Matsumoto; Tomoyuki Fujita
An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor.
Clinical endocrinology 1999;50(4):537-43.
1999: S Takeda; T Yoshizawa; Y Nagai; H Yamato; Seiji Fukumoto; K Sekine; Shigeaki Kato; T Matsumoto; Tomoyuki Fujita
Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice.
Endocrinology 1999;140(2):1005-8.
1999: Ryo Okazaki; Noriko Chikatsu; M Nakatsu; Yasuhiro Takeuchi; Miho Ajima; J Miki; Tomoyuki Fujita; M Arai; Y Totsuka; K Tanaka; Seiji Fukumoto
A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia.
The Journal of clinical endocrinology and metabolism 1999;84(1):363-6.
1998: Y Kodama; Yasuhiro Takeuchi; Miyuki Suzawa; Seiji Fukumoto; Hisashi Murayama; Hideyuki Yamato; Tomoyuki Fujita; T Kurokawa; Toshio Matsumoto
Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1998;13(9):1370-7.
1998: Seiji Fukumoto; Miyuki Suzawa; T Kikuchi; T Matsumoto; Shigeaki Kato; Tomoyuki Fujita
Cloning and characterization of kidney-specific promoter of human PTH/PTHrP receptor gene: absence of mutation in patients with pseudohypoparathyroidism type Ib.
Molecular and cellular endocrinology 1998;141(1-2):41-7.
1997: Ryo Okazaki; Y Totsuka; K Hamano; Miho Ajima; M Miura; Y Hirota; K Hata; Seiji Fukumoto; T Matsumoto
Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover.
The Journal of clinical endocrinology and metabolism 1997;82(9):2915-20.
1997: Y Kodama; Keiichi I Nakayama; H Fuse; Seiji Fukumoto; H Kawahara; H Takahashi; T Kurokawa; Chiharu Sekiguchi; Tetsuya Nakamura; Toshio Matsumoto
Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1997;12(7):1058-67.
1996: Seiji Fukumoto; Miyuki Suzawa; Y Takeuchi; Y Kodama; K Nakayama; E Ogata; T Matsumoto; Tomoyuki Fujita
Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib.
The Journal of clinical endocrinology and metabolism 1996;81(7):2554-8.
1996: K Nakayama; Seiji Fukumoto; S Takeda; Y Takeuchi; T Ishikawa; M Miura; K Hata; M Hane; Y Tamura; Yuetsu Tanaka; M Kitaoka; T Obara; E Ogata; T Matsumoto
Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.
The Journal of clinical endocrinology and metabolism 1996;81(2):607-11.
1994: Seiji Fukumoto; T Matsumoto; K Takebe; T Onaya; S Eto; H Nawata; E Ogata
Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
The Journal of clinical endocrinology and metabolism 1994;79(1):165-70.
1991: Seiji Fukumoto; T Matsumoto; S Harada; J Fujisaki; M Kawano; E Ogata
Pheochromocytoma with pyrexia and marked inflammatory signs: a paraneoplastic syndrome with possible relation to interleukin-6 production.
The Journal of clinical endocrinology and metabolism 1991;73(4):877-81.
1989: Toru Motokura; Seiji Fukumoto; T Matsumoto; S Takahashi; A Fujita; T Yamashita; Takashi Igarashi; E Ogata
Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma.
Annals of internal medicine 1989;111(6):484-8.
1989: Seiji Fukumoto; T Matsumoto; T Watanabe; H Takahashi; I Miyoshi; E Ogata
Secretion of parathyroid hormone-like activity from human T-cell lymphotropic virus type I-infected lymphocytes.
Cancer research 1989;49(14):3849-52.
1989: Seiji Fukumoto; T Matsumoto; H Yamoto; H Kawashima; Y Ueyama; N Tamaoki; E Ogata
Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production.
Endocrinology 1989;124(5):2057-62.
1989: Hideyuki Yamato; T Matsumoto; Seiji Fukumoto; K Ikeda; S Ishizuka; E Ogata
Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] metabolism in vitamin D-deficient rats infused with 1,25-(OH)2D3.
Endocrinology 1989;124(1):511-7.
1988: Toru Motokura; Seiji Fukumoto; S Takahashi; T Watanabe; T Matsumoto; Takashi Igarashi; E Ogata
Expression of parathyroid hormone-related protein in a human T cell lymphotrophic virus type I-infected T cell line.
Biochemical and biophysical research communications 1988;154(3):1182-8.
1988: K Ikeda; T Matsumoto; Seiji Fukumoto; Kiyoshi Kurokawa; Y Ueyama; K Fujishige; N Tamaoki; T Saito; K Ohtake; E Ogata
A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy.
Calcified tissue international 1988;43(2):97-102.
1988: Seiji Fukumoto; T Matsumoto; K Ikeda; T Yamashita; T Watanabe; K Yamaguchi; T Kiyokawa; K Takatsuki; N Shibuya; E Ogata
Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma.
Archives of internal medicine 1988;148(4):921-5.
1987: Seiji Fukumoto; T Matsumoto; Yuetsu Tanaka; S Harada; E Ogata
Renal magnesium wasting in a patient with short bowel syndrome with magnesium deficiency: effect of 1 alpha-hydroxyvitamin D3 treatment.
The Journal of clinical endocrinology and metabolism 1987;65(6):1301-4.
1987: T Matsumoto; K Ikeda; K Morita; Seiji Fukumoto; H Takahashi; E Ogata
Blood Ca2+ modulates responsiveness of renal 25(OH)D3-1 alpha-hydroxylase to PTH in rats.
The American journal of physiology 1987;253(5 Pt 1):E503-7.